Nuevolution

Nuevolution is a biopharmaceutical company specializing in the discovery and development of small molecule drug candidates for oncology and chronic inflammatory diseases. The company's core strength lies in its proprietary Chemsens platform, a sophisticated DNA-encoded library (DEL) technology that enables the screening of billions of molecules to identify high-affinity leads. This platform has facilitated numerous high-value collaborations with global pharmaceutical leaders, including Amgen, Janssen, and Novartis. Nuevolution's internal pipeline features programs targeting ROR gamma, BET, and IL-17A for various autoimmune and inflammatory conditions. In 2019, the company was acquired by Amgen for approximately $167 million to integrate its DEL technology and pipeline into Amgen's research organization.